Spironolactone-induced	spironolactone-induced	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
and	and	O	O
hyperkalemia	hyperkalemia	O	S_disease
in	in	O	O
patients	patients	O	O
with	with	O	O
heart	heart	O	B_disease
failure	failure	O	I_disease
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
A	a	O	O
previous	previous	O	O
randomized	randomized	O	O
controlled	controlled	O	O
trial	trial	O	O
evaluating	evaluating	O	O
the	the	O	O
use	use	O	O
of	of	O	O
spironolactone	spironolactone	S_chemicals	O
in	in	O	O
heart	heart	O	B_disease
failure	failure	O	I_disease
patients	patients	O	O
reported	reported	O	O
a	a	O	O
low	low	O	O
risk	risk	O	O
of	of	O	O
hyperkalemia	hyperkalemia	O	S_disease
(	(	B_chemicals	O
2	2	I_chemicals	O
%	%	O	O
)	)	O	O
and	and	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
(	(	O	O
0	0	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Because	because	O	O
treatments	treatments	O	O
for	for	O	O
heart	heart	O	B_disease
failure	failure	O	I_disease
have	have	O	O
changed	changed	O	O
since	since	O	O
the	the	O	O
benefits	benefits	O	O
of	of	O	O
spironolactone	spironolactone	S_chemicals	O
were	were	O	O
reported	reported	O	O
,	,	O	O
the	the	O	O
prevalence	prevalence	O	O
of	of	O	O
these	these	O	O
complications	complications	O	O
may	may	O	O
differ	differ	O	O
in	in	O	O
current	current	O	O
clinical	clinical	O	O
practice	practice	O	O
.	.	O	O

We	we	O	O
therefore	therefore	O	O
sought	sought	O	O
to	to	O	O
determine	determine	O	O
the	the	O	O
prevalence	prevalence	O	O
and	and	O	O
clinical	clinical	O	O
associations	associations	O	O
of	of	O	O
hyperkalemia	hyperkalemia	O	S_disease
and	and	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
in	in	O	O
heart	heart	O	B_disease
failure	failure	O	I_disease
patients	patients	O	O
treated	treated	O	O
with	with	O	O
spironolactone	spironolactone	S_chemicals	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
We	we	O	O
performed	performed	O	O
a	a	O	O
case	case	O	O
control	control	O	O
study	study	O	O
of	of	O	O
heart	heart	O	B_disease
failure	failure	O	I_disease
patients	patients	O	O
treated	treated	O	O
with	with	O	O
spironolactone	spironolactone	S_chemicals	O
in	in	O	O
our	our	O	O
clinical	clinical	O	O
practice	practice	O	O
.	.	O	O

Cases	cases	O	O
were	were	O	O
patients	patients	O	O
who	who	O	O
developed	developed	O	O
hyperkalemia	hyperkalemia	O	S_disease
(	(	O	O
K(+	k(+	B_chemicals	O
)	)	I_chemicals	O
>	>	O	O
5.0	5.0	O	O
mEq/L	meq/l	O	O
)	)	O	O
or	or	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
(	(	O	O
Cr	cr	O	O
>	>	O	O
or=2.5	or=2.5	O	O
mg/dL	mg/dl	O	O
)	)	O	O
,	,	O	O
and	and	O	O
they	they	O	O
were	were	O	O
compared	compared	O	O
to	to	O	O
2	2	O	O
randomly	randomly	O	O
selected	selected	O	O
controls	controls	O	O
per	per	O	O
case	case	O	O
.	.	O	O

Clinical	clinical	O	O
characteristics	characteristics	O	O
,	,	O	O
medications	medications	O	O
,	,	O	O
and	and	O	O
serum	serum	O	O
chemistries	chemistries	O	O
at	at	O	O
baseline	baseline	O	O
and	and	O	O
follow-up	follow-up	O	O
time	time	O	O
periods	periods	O	O
were	were	O	O
compared	compared	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Sixty-seven	sixty-seven	O	O
of	of	O	O
926	926	O	O
patients	patients	O	O
(	(	O	O
7.2	7.2	O	O
%	%	O	O
)	)	O	O
required	required	O	O
discontinuation	discontinuation	O	O
of	of	O	O
spironolactone	spironolactone	S_chemicals	O
due	due	O	O
to	to	O	O
hyperkalemia	hyperkalemia	O	S_disease
(	(	O	O
n	n	O	O
=	=	O	O
33	33	O	O
)	)	O	O
or	or	O	O
renal	renal	O	B_disease
failure	failure	O	I_disease
(	(	O	O
n	n	O	O
=	=	O	O
34	34	O	O
)	)	O	O
.	.	O	O

Patients	patients	O	O
who	who	O	O
developed	developed	O	O
hyperkalemia	hyperkalemia	O	S_disease
were	were	O	O
older	older	O	O
and	and	O	O
more	more	O	O
likely	likely	O	O
to	to	O	O
have	have	O	O
diabetes	diabetes	O	O
,	,	O	O
had	had	O	O
higher	higher	O	O
baseline	baseline	O	O
serum	serum	O	O
potassium	potassium	O	O
levels	levels	O	O
and	and	O	O
lower	lower	O	O
baseline	baseline	O	O
potassium	potassium	O	O
supplement	supplement	O	O
doses	doses	O	O
,	,	O	O
and	and	O	O
were	were	O	O
more	more	O	O
likely	likely	O	O
to	to	O	O
be	be	O	O
treated	treated	O	O
with	with	O	O
beta-blockers	beta-blockers	S_chemicals	O
than	than	O	O
controls	controls	O	O
(	(	O	O
n	n	O	O
=	=	O	O
134	134	O	O
)	)	O	O
.	.	O	O

Patients	patients	O	O
who	who	O	O
developed	developed	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
had	had	O	O
lower	lower	O	O
baseline	baseline	O	O
body	body	O	B_disease
weight	weight	O	I_disease
and	and	O	O
higher	higher	O	O
baseline	baseline	O	O
serum	serum	O	O
creatinine	creatinine	S_chemicals	O
,	,	O	O
required	required	O	O
higher	higher	O	O
doses	doses	O	O
of	of	O	O
loop	loop	B_chemicals	O
diuretics	diuretics	S_chemicals	O
,	,	O	O
and	and	O	O
were	were	O	O
more	more	O	O
likely	likely	O	O
to	to	O	O
be	be	O	O
treated	treated	O	O
with	with	O	O
thiazide	thiazide	B_chemicals	O
diuretics	diuretics	S_chemicals	O
than	than	O	O
controls	controls	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Spironolactone-induced	spironolactone-induced	O	O
hyperkalemia	hyperkalemia	O	S_disease
and	and	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
are	are	O	O
more	more	O	O
common	common	O	O
in	in	O	O
our	our	O	O
clinical	clinical	O	O
experience	experience	O	O
than	than	O	O
reported	reported	O	O
previously	previously	O	O
.	.	O	O

This	this	O	O
difference	difference	O	O
is	is	O	O
explained	explained	O	O
by	by	O	O
patient	patient	O	O
comorbidities	comorbidities	O	O
and	and	O	O
more	more	O	O
frequent	frequent	O	O
use	use	O	O
of	of	O	O
beta-blockers	beta-blockers	S_chemicals	O
.	.	O	O

